Lycera Corp. Company Profile
Lycera Corp. is focused on the discovery and development of small-molecule immunomodulators for the treatment of immunologic diseases, including psoriasis, rheumatoid arthritis, lupus erythematosis, inflammatory bowel disease and transplant rejection. Originally founded by Dr. Gary Glick as a spin-out of the University of Michigan, Lycera is developing drug candidates that target two novel therapeutic pathways and have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents. Visit www.lycera.com for more information.
News Articles
[Merck] and [Lycera] enter into second agreement; could be worth over $300mm
Autoimmune disease drug developer [Lycera Corp.] has entered into its second agreement with [Merck & Co.] in two years. Through a broader deal the current collaboration could bring Lycera over $300mm....
Merck, Lycera broaden partnership on autoimmune disease drugs
Merck & Co. expanded a collaboration with Lycera to develop and market small-molecule drugs against autoimmune diseases. -More-
Lycera, Merck partner to develop autoimmune disease therapeutics
Biopharmaceutical company Lycera and Merck, referred to as MSD outside the US and Canada, have collaborated to discover and develop and commercialize therapies targeting a range of immune-mediated dis...
Second Merck deal takes Lycera's autoimmune quiver to potential $600m+
Lycera's second collaboration with Merck, which is worth more than $300 million in upfront and future milestone fees plus royalties, gives the Ann Arbor, Michigan-based company a third drug discovery...
Lycera Corp. (Ann Arbor, Mich.) partnered with Merck & Co. Inc. (NYSE:MRK) to discover, develop and commercialize small molecules against undisclosed targets for autoimmune diseases. Lycera will recei...
Merck enters second autoimmune disorder collaboration with Lycera
Merck and Lycera have agreed to build on their first collaboration from 2011 with a new US $300m agreement to discover and develop therapies for autoimmune disorders. Merck is entering into a second...
Who Needs a CEO? Lycera Strikes Deal with Pharma Giant Merck
Lycera founder and chief scientific officer Gary Glick is feeling pretty good these days. And who can blame him? Just last fall, CEO Bill Sibold left the Plymouth, MI-based drug startup after less tha...
Lycera Enters Into Second Collaboration Deal with Merck
Lycera, the biopharmaceutical company based in Plymouth, MI, announced today that it is entering into a second collaboration agreement with pharmaceutical giant Merck. This is the second collaboration...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Lycera Corp. is focused on the discovery and development of small-molecule immunomodulators for the treatment of immunologic diseases, including psoriasis, rheumatoid arthritis, lupus erythematosis, i...
Lycera Corp. is focused on the discovery and development of selective, small-molecule immunomodulators for the treatment of patients with autoimmune diseases such as rheumatoid ar...
More Information about "Lycera Corp." on BioPortfolio
We have published hundreds of Lycera Corp. news stories on BioPortfolio along with dozens of Lycera Corp. Clinical Trials and PubMed Articles about Lycera Corp. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lycera Corp. Companies in our database. You can also find out about relevant Lycera Corp. Drugs and Medications on this site too.
